Lindbrook Capital’s Akebia Therapeutics AKBA Stock Holding History

Lindbrook Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-207	Closed	-$1K	–	1843
2021 Q2	$1K	Hold	207	–	–	﹤0.01%	1693
2021 Q1	$1K	Buy	+207	New	+$746	﹤0.01%	1654
2020 Q4	–	Sell	-93	Closed	–	–	1765
2020 Q3	$0	Hold	93	–	–	﹤0.01%	1730
2020 Q2	$1K	Hold	93	–	–	﹤0.01%	1498
2020 Q1	$1K	Buy	+93	New	+$724	﹤0.01%	1370

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lindbrook Capital's AKBA Position: Q3 2021 in Review

Lindbrook Capital sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 207 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in AKBA in Q1 2020 and held it in 5 quarters. The position peaked at $1K in Q2 2021. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

Lindbrook Capital reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
Lindbrook Capital sold 207 Akebia Therapeutics shares in Q3 2021, an estimated $1K.
Lindbrook Capital first reported a position in Akebia Therapeutics in Q1 2020 and held it in 5 quarters.
Lindbrook Capital's Akebia Therapeutics position peaked at $1K in Q2 2021.
126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.